Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson (JNJ) stock fell as the company lowered full-year earnings outlook while reporting better-than-expected Q3 ...

Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected ...

We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...

Johnson & Johnson MedTech (NYSE: JNJ) today announced the first completed commercial case with its Varipulse platform in ...

JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on third-quarter financial results and a surgical ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...

Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the first phase of the VOLT™ ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...